MRI in advanced ovarian cancer: multicentre MISSION trial.
European Journal of Cancer · 2026
DOI: 10.1016/j.ejca.2026.116614 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Eva Berardi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, the Netherlands; Department of Radiology, San Camillo …. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Ovarian Neoplasms, Cytoreduction Surgical Procedures, Peritoneal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Netherlands Organisation for Health Research and Development.
Abstract (Originalsprache)
BACKGROUND: For patients with advanced ovarian cancer, complete cytoreductive surgery (CRS) offers the best chance for long-term survival and cure. Currently, staging relies on CT and, in selected cases, diagnostic laparoscopy, both of which have important limitations. This study assessed the diagnostic performance of MRI for predicting complete interval CRS. METHODS: This prospective multicentre cohort study included FIGO stage III-IV ovarian cancer patients scheduled for interval CRS. Radiologists, blinded to surgical findings, independently scored the MRI-derived Peritoneal Cancer Index (mriPCI). Gynaecologic oncologists recorded the surgical PCI (sPCI) before and after intraoperative disclosure of MRI findings (revised-sPCI). The primary endpoint was the ability of mriPCI to predict complete interval CRS (no macroscopic residual disease). Secondary endpoints included concordance between mriPCI and sPCI, diagnostic yield from MRI disclosure, and inter-reader agreement. Sample size calculations indicated that 189 patients undergoing interval CRS should be included. RESULTS: Between 2018 and 2023, 270 patients were recruited, of whom 194 were eligible for analysis. Complete interval CRS was achieved in 149/194 patients (77%). The diagnostic performance of mriPCI showed an AUC of 0.76 for predicting a complete CRS. The revised-SPCI, after intraoperative disclosure of MRI led to an AUC of 0.88. MRI findings led to a change in sPCI in 19% of patients. Interobserver reliability for mriPCI was substantial (Interclass correlation coefficient 0.81, 95% CI 0.67-0.88). CONCLUSIONS: MRI enables accurate, non-invasive prediction of complete interval CRS feasibility in advanced ovarian cancer. Integration of MRI into surgical planning enhances intraoperative detection of lesions and can facilitate decision-making, supporting its role as a non-invasive staging tool. TRIAL REGISTRATION NUMBER: NCT03399344.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, the Netherlands; Department of Radiology, San Camillo Forlanini Hospital, Circonvallazione Gianicolense, 87, Rome 00152, Ita…
- Center of Gynaecologic Oncology, location The Netherlands Cancer Institute, Department of Gynaecology, Amsterdam, the Netherlands.
- Department of Gynaecology and Obstetrics, Catharina Hospital, Michelangelolaan 2, Eindhoven 5623 EJ, the Netherlands.
- Department of Gynaecology, Leiden University Medical Centre, Albinusdreef 2, P.O. Box 9600, Leiden 2300 RC, the Netherlands.
- Department of Radiology, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, Leiden 2300 RC, the Netherlands.
- Department of Radiology, Catharina Hospital, Michelangelolaan 2, Eindhoven 5623 EJ, the Netherlands.
Förderung
- Netherlands Organisation for Health Research and Development
Zitieren
APA
Berardi, E., J van Driel, W., H M Hermans, R., N Gaarenstroom, K., A R Lok, C., Persijn-van Meerten, E. L. V., Nederend, J., Lambrechts, S., Lopez-Yurda, M., P Engbersen, M., J V Rijsemus, C., M J Lambregts, D., Laghi, A., G J Aalbers, A., G H Beets-Tan, R., F M Kok, N., & J Lahaye, M. (2026). MRI in advanced ovarian cancer: multicentre MISSION trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116614
Vancouver
Berardi E, J van Driel W, H M Hermans R, N Gaarenstroom K, A R Lok C, Persijn-van Meerten ELV, et al. MRI in advanced ovarian cancer: multicentre MISSION trial. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116614
BibTeX
@article{Berardi2026,
author = {Berardi, Eva and J van Driel, Willemien and H M Hermans, Ralph and N Gaarenstroom, Katja and A R Lok, Christianne and Persijn-van Meerten, Els L van and Nederend, Joost and Lambrechts, Sandrina and Lopez-Yurda, Marta and P Engbersen, Maurits and J V Rijsemus, Charlotte and M J Lambregts, Doenja and Laghi, Andrea and G J Aalbers, Arend and G H Beets-Tan, Regina and F M Kok, Niels and J Lahaye, Max},
title = {MRI in advanced ovarian cancer: multicentre MISSION trial},
journal = {European Journal of Cancer},
year = {2026},
doi = {10.1016/j.ejca.2026.116614}
}
EUVIMED